Registering a CAGR of 8.8% over the forecast period of 2022-2027, the global Pancreatic Cancer Diagnostic market is anticipated to reach the market value of US$ 6224 million in the year 2027 from US$ 3865 million in the year 2021.
Pancreatic Cancer Diagnostics Market Size & Market Analysis
Pancreatic cancer arises when there is an uncontrollable growth of cells in the pancreas. Pancreatic cancer is categorized as exocrine and endocrine, based on the cells affected by cancer. Exocrine cells in the pancreas generate pancreatic enzymes. When cancer manifests in these cells, it is referred to as exocrine pancreatic cancer. Endocrine cells are a small cluster of cells and are also called islets of Langerhans. These cells create hormones, such as insulin and glucagon, releasing them into the blood flow.
Chemotherapy is one of the main cancer treatments that kill pancreatic cancer cells by preventing them from growing and dividing. These drugs are systemic treatments; the drugs travel through the bloodstream and damage cancer cells throughout the body. Unfortunately, chemotherapy can damage some healthy cells and cause major side effects. Chemotherapy may shrink and/or prevent the growth of pancreatic tumors. Factors such as the increasing prevalence and incidence of pancreatic cancer and advancements in molecular biology, development of drugs, and diagnostic technology play a major part in market growth. With the increase in R&D initiatives, favorable reimbursement scenarios, and the launch of novel products, the market is expected to grow significantly during the forecast period.
Who are the Major Players in Pancreatic Cancer Diagnostic Market?
The global Pancreatic Cancer Diagnostic includes the identification and analysis of the various market participants competing in the global market. Prominent competitors include Siemens, GE Healthcare Inc. (Other OTC:GENN), Roche Holding AG (Other OTC :RHHBY), Philips Healthcare, Danaher Corporation (NYSE :DHR), Canon Medical Systems, Abbott Laboratories (NYSE:ABT), Hitachi Medical, Qiagen N.V. (NYSE:QGEN), Apexigen Inc., Myriad Genetics,Inc. (NasdaqGS:MYGN)and Others.
What are the major Applications, Types and Regions for Pancreatic Cancer Diagnostic Market?
By Type, it is segmented into
- Imaging
- Tumor Biomarker
- Biopsy
By Application, it is segmented into
- Hospitals
- Clinics
Pancreatic Cancer Diagnostic Market Regional Analysis
The United States is anticipated to retain its significant market share due to the rising incidence of pancreatic cancers, supportive reimbursement policies, and high healthcare spending.
As per a 2018 publication in the MedCrave Gastroenterology and Hepatology journal, pancreatic cancer was the ninth most frequent cancer, despite its moderate incidence. It was estimated to be among the second-deadliest cause of cancer by 2027. Also, according to the GLOBOCAN 2020 report, about 56,734 new cases of pancreatic cancer were reported in 2020.
Pancreatic Cancer Diagnostics Market Size & Market Analysis
Source :https://www.industrydataanalytics.com/reports/pancreatic-cancer-diagnostic-market